Kornimate/medical-research-clean huggingface dataset:
reducing aggression in children and adolescent on an inpatient unit

Conditions: Anger; Aggression

Summary: the purpose of this study is to determine whether anger control therapy (act) with regulate and gain emotional-control (rage-control) is a feasible behavioral therapy to provide on a pediatric inpatient psychiatric unit.

aggression and disruptive behavior are the most common reasons for child and adolescent inpatient psychiatric hospitalization. aggressive children and adolescents who merit admission to inpatient psychiatric hospitals for treatment typically display dramatic problems with self-regulation that interfere with global adaptive functioning. the goal of this study is to teach self-regulation techniques by combining cognitive behavioral therapy with a biofeedback video game in effort to motivate patients to learn and practice these coping skills, which will translate to decreased feelings of anger and aggression while hospitalized.

Eligibility criteria:
inclusion criteria: * consecutive admissions to the psychiatric inpatient unit between the ages of 9 and 17 years of age * who were not expected to begin or undergo a change \>25% to their antipsychotic or mood stabilizing medications * elevated levels of anger as demonstrated by baseline score on the state trait anger expression inventory - child and adolescent (staxi-ca) combined state-anger and trait-anger score greater than 30. exclusion criteria: * inability to consent, comprehend, and effectively participate in the study. * gross cognitive impairment due to mental retardation, dementia, or intoxication. * started on an antipsychotic or mood stabilizing drug within 5 days of beginning the study

Keywords: anger aggression cbt videogame biofeedback
whey permeate study

Conditions: Malnutrition

Summary: this is a prospective, randomized, double-blinded, controlled clinical effectiveness trial of two supplementary foods in the treatment of mam. specific aim 1: test the effectiveness of two supplementary foods, whey rusf and soy rusf, in the treatment of mam in 6-59 month old children in a 12-week home-based supplementary feeding program. hypothesis: the proportion of children who recover receiving either soy or whey rusf will differ by no more than three percent.

this will be a randomized, double-blinded, controlled clinical effectiveness trial assessing the treatment of moderate acute malnutrition (mam) with one of two supplementary foods for a period of up to 12 weeks. the overall purpose of this research is to see if your child will grow and gain weight more rapidly using one of two peanut butter foods as he/she recovers from protein-energy malnutrition. subjects will be given a soy or dairy peanut butter food at their home. the peanut butter food has either small amounts of soya protein and minerals (iron, zinc) or whey powder and minerals added to them. subjects will have enough food to feed the child for 2 weeks, and asked to return every 2 weeks to be weighed, measured and given more food. the parents of the subjects will be asked to feed their child this food until his/her weight has returned to what is considered normal for the child's height. subjects will then return after 3, 6 and 12 months for a check-up. at these check-ups, he/she will be measured and examined. the current standard of care is to allow the child to recover without food or with supplemental flour thus all participation is related to research. participation in this study is expected to last 8-12 weeks of therapy with follow up in 12 months after completion of the therapy.

Eligibility criteria:
inclusion criteria: * children with mam defined as mid-upper-arm circumference, muac, ≤ 12.5 cm and \> 11.5 cm without bipedal edema. exclusion criteria: * children simultaneously involved in another research trial or supplemental feeding program * children with developmentally delayed * children with a chronic debilitating illness such as cerebral palsy (not including hiv or tb) * children with a history of peanut or milk allergy * children will also be excluded if they had received therapy for acute malnutrition within one month prior to presentation.

Keywords: mam
hypoxia-induced autophagy in the pathogenesis of map

Conditions: Hypoxia; Autophagy; Placenta; Morbidly Adherent Placenta

Summary: to investigate the role of hif 1α and lc3b in the pathogenesis of map, to evaluate the role of mmp-9 in the antenatal prediction of map, and to compare the expression of hif1α, lc3b, and level mmp-9 between patients of placenta previa with map and patients with normal placentation.

cesarean section (cs) rate has been rising rapidly in the recent years.one of the complications of repeated cs is placenta previa, an implantation of placenta on or near internal os. morbidly adherent placenta (map), known also as placenta accreta spectrum, has histopathologic and clinical types. the placenta becomes abnormally adherent to the uterine wall, fails to separate leading to massive blood loss and possible hysterectomy. the risk of map in patient with placenta previa increases with repeated cs. theories for development of map include abnormal trophoblastic invasion of myometrium, abnormal decidualization, neovascularization and reduction of apoptosis of trophobalsts. in early pregnancy: the trophoblasts invade spiral arteries and reduce blood flow to the placenta 00leading to hypoxia. hypoxia inducible factor 1 alpha (hif-1α), a protein involved in cellular adaptation to hypoxia, increases throughout pregnancy and contributes in the invasion of trophoblasts. excessive invasion in map might prolong the hypoxia, increasing the expression of hif1α. autophagy is a process for managing and removing the damaged organelles and cellular proteins in hypoxia. it supports the trophoblasts. hypoxia induced autophagy markers such as lc3b might be enhanced by map. matrix metalloproteinase-9 (mmp-9) plays an important role in cell invasion and placental implantation. disturbance of mmp-9 might alter the trophobalsts invasion resulting in map . the investigators hypothesize that hypoxia, autophagy and invasiveness are linked to the pathophysiology of map, so we will assess the expression of hif1α, lc3b to estimate their role beside mmp-9.

Eligibility criteria:
inclusion criteria: 1. gestational age: more than 28 weeks up to 40 weeks. 2. pregnant women with at least one previous cs. 3. singleton pregnancy. 4. patient known to have placenta previa by 2d ultrasound. 5. heamodynamically stable patient. exclusion criteria: 1. multiple pregnancy. 2. gestational age less than 28 weeks. 3. heamodynamically unstable patient. 4. hypertensive disorder with pregnancy. 5. gestational diabetes. 6. iugr. 7. patient with bleeding tendency or using anticoagulant.

Keywords: hif1α hypoxia-induced autophagy lc3b invasion-related markers mmp-9 morbidly adherent placenta
diffusion-weighted mri to predict treatment response in stereotactic radiotherapy of central nervous system (cns) metastases

Conditions: Radiotherapy; Brain Metastases; Sensitivity; Radionecrosis

Summary: stereotactic radiation therapy is an important and common method of treating brain metastases in patients with malignant disease. today, however, there are no methods available to determine the metastasis' radiation sensitivity in advance and treatment responses can only be seen by changing of the size of the metastasis on conventional x-ray examinations, computed tomography (ct) and magnetic resonance imaging (mri). changes in the size of the metastases is something that is often seen weeks / months after treatment is completed. at lund university hospital, a new imaging technique, diffusional variance decomposition (divide), has now been developed. with this technique, the scatter in isotropic and anisotropic diffusion can be measured for each measuring point, which provides significantly more information about the properties of the tissue compared to current methods.


Eligibility criteria:
inclusion criteria: 1. patients prescribed stereotactic radiation therapy to the brain, where mri imaging is included in the treatment preparations. 2. cohesive remaining solid tumor component of ≥10mm. 3. age ≥18 years. 4. world health organisation (who) performance status 0-1. exclusion criteria: 1. inability to decide for oneself on participation in the study. 2. inability to understand the swedish language. 3. metastases close to the base of the skull. 4. contraindications to conducting an mri examination. 5. contraindications to obtaining contrast media during mri examination. 6. expected survival less than 6 months. 7. previous radiation treatment to the same site in the brain, i.e. current treatment is a rope radiation. -

Keywords: diffusional variance decomposition divide brain metastasis radiation treatment treatment response radionecrosis radiation damage radiation sensitivity magnetic resonance imaging
study of brain-gut function reconstruction after intersphincteric resection for ultra-low rectal tumors

Conditions: Rectal Neoplasms

Summary: to investigate the effects of intersphincteric resection (isr) of ultra-low rectal tumor on the brain-rectoanal function of patients, and to precisely localize the cerebral functional regulatory regions for intervention targets of anorectal remodeling. utilizing transcranial magnetic stimulation(tms) technology to explore the functional remodeling of the "new" anorectal muscle groups and provide a theoretical basis for more research on the rehabilitation and mechanism of fecal incontinence.

this study is a single-center phase ii, open, three-arm clinical trial. we prospectively enroll patients who undergo isr for ultra-low rectal tumor in the department of general surgery, huashan hospital, fudan university. patients with ileostomy closure are randomly divided into two groups (tms group and false stimulation group), and healthy volunteers were recruited. the differences of task-state fmri between healthy volunteers, and isr patients (both preoperative and postoperative) are compared, combined with rectal function scores (wexner score, lars score) and quality of life scale (eortc qlq-c30, eortc qlq-cr38). proctoanal manometry are used to find the precise location of the proctoanal motor function area in the cerebral cortex, and to evaluate the effect and value of tms on postoperative anorectal motor function remodeling in patients with isr.

Eligibility criteria:
inclusion criteria: * primary ultra-low rectal tumor patient who is received intersphincteric resection and preventive ileostomy was performed. * patient who is willing to participate in the study, and voluntarily sign informed consent. exclusion criteria: * anastomotic leakage or other serious complications occur after surgery. * advanced tumor, tumor recurrence or metastasis. * patients with contraindications of fmri scanning, such as history of metal implants in the body, claustrophobia, etc. * patients with contraindications for tms treatment, such as intracranial metal implants, epilepsy history, heart disease with unstable heart function, retinal detachment, etc. * combined with organic brain disease and drug abuse history. * combined with other mental diseases. * pregnant or lactating women.

Keywords: ultra-low rectal tumors intersphincteric resection transcranial magnetic stimulation fmri
efficacy and safety study of gk530g versus cd0271 0.1% gel and cd1579 2.5% gel in the treatment of acne vulgaris.

Conditions: Acne Vulgaris

Summary: this study is to demonstrate the superiority in efficacy of the gk530g (fixed combination of cd0271 0.1% and cd1579 2.5%) versus each of the monads (cd0271 0.1% and cd1579 2.5%) in the treatment of acne vulgaris for up to 12 weeks, in the japanese patients.


Eligibility criteria:
inclusion criteria: * men and women at the age of 12 or older at the screening visit. * those with clinical diagnosis of acne vulgaris with more than 20 noninflammatory lesions (open and closed comedones) and 12 to 100 (inclusive) inflammatory lesions (papules, pustules and nodules) on the face (forehead, both cheeks, nose and chin). exclusion criteria: * those with more than two nodular acne lesions or any cysts. * those with the diagnosis of any acne conglobata, any acne fulminans, any chloracne, or any drug induced acne. * those who have clinically significant abnormal findings or conditions on skin other than acne such as atopic dermatitis, perioral dermatitis, or rosacea that potentially interfere with study assessments according to investigator's judgment.

Keywords: acne vulgaris
esmolol in sepsis management:evaluating immunomodulatory effects and impact on patient outcomes

Conditions: Sepsis; Lymphocyte Disorder T; Immunologic Paralysis; Catecholamine; Overproduction; Beta-Blocker; Cytokine Storm; Sympathetic Nervous System Diseases

Summary: evaluate the effectiveness of esmolol, a selective β1-adrenergic receptor blocker, in modulating immune responses and improving patient outcomes in sepsis.

the research aimed to investigate the immunomodulatory effects of esmolol in sepsis treatment. a comprehensive study was conducted, incorporating both direct experimental assays and data extraction from electronic health records (ehr) to evaluate physiological and immunological responses in septic patients. specifically, norepinephrine (ne) levels were measured, and cd4+/cd8+ t cells were quantified to assess changes influenced by esmolol administration. additionally, cytokine profiles, procalcitonin (pct) levels, complete blood counts (cbc), and routine biochemical functions were monitored through data retrieved from ehr systems, providing a broad perspective on patient health and response to treatment. this multifaceted approach aimed to determine how esmolol affects key immune parameters and overall patient outcomes, addressing both the direct and systemic impacts of this treatment on septic patients.

Eligibility criteria:
inclusion criteria: 1. patients aged between 18 and 90 years. 2. diagnosed with sepsis or septic shock according to the diagnostic criteria in suivival sepsis of 2021. 3. received adequate fluid resuscitation and necessary exogenous norepinephrine (ne). 4. no contraindications to esmolol and appropriate heart rate levels determined by clinical assessment. 5. provided written informed consent. exclusion criteria: 1. deceased within three days following icu admission. 2. pregnant or lactating individuals. 3. underwent surgical procedures within the last two weeks. 4. severe cardiac failure exceeding nyha class iii. 5. usage of long-term oral β-blockers or any form of extracorporeal circulation within the last two weeks. 6. presenting with sinus bradycardia or atrioventricular block. 7. received high doses of corticosteroids in the past three months. 8. underwent significant hormone therapy, persistent blood loss of more than 500 ml within any 24-hour period, or were treated with esmolol for less than three days.

Keywords: esmolol sepsis immune modulation t-cell function inflammatory markers sympathetic nervous system
trial of small intestine submucosa (sis) mesh for anterior repair: a pilot study

Conditions: Anterior Pelvic Organ Prolapse

Summary: prolapse occurs when pelvic organs drop down and cause a bulging of the tissues. an "anterior wall prolapse" occurs when the front of the vagina loses its support, and the bladder drops down and rotates into the vaginal opening. the bladder can cause a bulge out of the vagina. one of the treatment options available is to repair the anterior wall surgically. the goals of surgery are to return the anatomy to its usual position, ensuring that all the pelvic floor organs (bladder, vagina and rectum) can function properly. the ideal surgical repair would also be long lasting. two surgical options are routinely performed in calgary for repair of an anterior compartment prolapse. one option involves fixing the organs back in place using sutures. the other option uses sutures plus a mesh made of small intestine submucosa (sis) that is already licensed for use in canada. the sis mesh is slowly absorbed after it is placed in the pelvic area. the investigators do not know which of these two options is the best surgical procedure. both may have different advantages that would result in better results. this study is designed to try and find out if one of these procedures is better, and if a larger study may be needed.


Eligibility criteria:
inclusion criteria: * women who require surgical correction for anterior compartment prolapse. (concomitant surgery is permitted.) * point ba of 0 or greater: that is a positive ba, indicating that the prolapse is beyond the introitus, not within the vagina. * patient must consent to participate in the study. exclusion criteria: * having an obliterative procedure (lefort procedure or colpocleisis). * allergy to graft material. * immunocompromised. * previous anterior compartment repair. * are unable to understand english. * will be unavailable for follow-up.

Keywords: anterior pelvic organ prolapse surgical repair pelvic floor surgery randomized clinical trial
virtual reality software to reduce stress in cancer patients

Conditions: Breast Cancer; Head and Neck Cancer

Summary: the purpose of this study is to test the ability of virtual reality-based social support to increase patient adherence to radiation therapy by reducing patient distress.

this study will involve patients who have been diagnosed with breast or head and neck cancer and are suitable to receive radiation therapy. it is a single arm pilot trial designed to provide information on the safety, feasibility, and impacts of incorporating virtual reality (vr) software into the treatment plan of patients receiving radiation therapy with the goal of increasing patient adherence to radiation therapy. patients will be provided with vr-based education sessions prior to and during the course of radiation therapy. patients' emotional and social distress levels will be assessed with questionnaires to measure the impacts of the vr software. patients will be in the study for up to 3 months during regular cancer care, but the total time for the study procedures is anticipated to be 2-4 hours in total. results from this study will be for research only and will not impact treatment decisions.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old 2. must be able to read and speak english 3. diagnosis of breast or head and neck cancer 4. treatment plan includes radiotherapy within the next 2 months 5. signed study-specific informed consent prior to study entry exclusion criteria: 1. previous radiation therapy treatment 2. neurologic deficits 3. visual disorder 4. neuro-psychiatric disorder 5. use of neuro-psychiatric drugs

Keywords: virtual reality radiation therapy education distress stress
determining the maximum tolerated dose of low dose interferon-alpha in conjunction with nilotinib in pretreated philadelphia chromosome positive (ph+) chronic myeloid leukemia patients in chronic phase (cml-cp)

Conditions: Chronic Myeloid Leukemia

Summary: this study will assess the maximum tolerated dose of low dose interferon in conjunction with nilotinib in pretreated philadelphia chromosome positive (ph+) chronic myeloid leukemia patients in chronic phase (cml-cp).


Eligibility criteria:
inclusion criteria: * patients with chronic myeloid leukemia in chronic phase (cml-cp) at screening * initial diagnosis of cml cytogenetically confirmed by the presence of the ph+ metaphases from the bone marrow * patients who have been treated with nilotinib for a minimum of 6 months (1 month represents 28 days) after switch from previous cml treatments * patients who have been treated with stable dosing of 2x400mg nilotinib within the last month before start of study treatment * no grade 3-4 ctc toxicities on nilotinib alone in the last month preceding the start of the study regimen exclusion criteria: * patients who are considered ph- because they do not have a confirmed cytogenetic diagnosis of the t(9;22) translocation in their bone marrow metaphases * evidence of a point mutation within the bcr-abl gene leading to a clinically relevant amino acid exchange in the kinase domain at position t315 (gatekeeper mutation t315i) * impaired cardiac function * severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or uncontrolled infection). other protocol-defined inclusion/exclusion criteria may apply

Keywords: chronic myeloid leukemia interferon alfa nilotinib combination cml philadelphia chromosome positive (ph+) chronic myeloid leukemia patients in chronic phase (cml-cp) after switch from previous cml treatment
transcare - genital surgery for trans women in centralized vs. decentralized health care delivery settings

Conditions: Gender Dysphoria; Gender Identity Disorder; Transsexualism; Gender Identity

Summary: trans (i.e., transgender, transsexual) individuals experience a gender that does not match their sex assigned at birth (gender incongruence), which can lead to distress called gender dysphoria (formerly known as transsexualism). trans health care (thc) is primarily focusing on transition-related medical interventions (e.g. genital surgery) to reduce gender dysphoria and improve the quality of life. to date, trans individuals access thc services in both decentralized (e.g., various transition-related interventions are spread over several locations) and centralized structures (e.g., gender affirmative medical treatments are provided by a single source). the transcare study examines genital surgery for trans women (e.g. penile inversion vaginoplasty), focusing on the effect of different health care delivery settings (e.g., if patients received all treatments from a single source or spread over several locations) on psychosocial outcomes and the quality of healthcare.


Eligibility criteria:
inclusion criteria: * age 16 years or older; * gender different from their assigned male sex at birth * current or new surgical care patient at department of urology at the university medical center hamburg-eppendorf * able to read, speak, and understand german * written informed consent after written and oral information exclusion criteria: * under 16 years of age * missing informed consent * unable to speak german